2929 7TH STREET, SUITE 105, BERKELEY, CA
Earnings Release
Other Events
News
Financial Results, Costs of Shutting Down or Selling Parts of the Business, Other Events
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Appoints Sri Ryali as Chief Financial Officer
Q2
Q1
FY 2024
Q3
FY 2023
Q2 amended
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-1MEF